Amneal Pharmaceuticals, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDAmneal Pharmaceuticals, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 85), indicating clear outperformance against the broad market. Earnings growth of 210% provides fundamental context to the price action. However, with RSI at 78, the stock is extended and may be prone to a short-term pullback.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $14.36 | +12.20% | ABOVE |
| 50 SMA | $13.42 | +20.02% | ABOVE |
| 100 SMA | $13.41 | +20.18% | ABOVE |
| 150 SMA | $13.13 | +22.69% | ABOVE |
| 200 SMA | $12.42 | +29.71% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is AMRX in an uptrend right now?
AMRX has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, AMRX is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is AMRX overbought or oversold?
AMRX's RSI (14) is 78. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is AMRX outperforming the market?
AMRX has a Relative Strength (RS) Rating of 85 out of 99. Yes, AMRX is a market leader, outperforming 85% of all stocks over the past 12 months.
Where is AMRX in its 52-week range?
AMRX is trading at $16.11, which is 97% of its 52-week high ($16.61) and 94% above its 52-week low ($7.67).
How volatile is AMRX?
AMRX has a Beta of 0.87 and 52-week volatility of 32%. It's less volatile than the S&P 500 - generally more stable.